BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Eslami G, Mousaviasl S, Radmanesh E, Jelvay S, Bitaraf S, Simmons B, Wentzel H, Hill A, Sadeghi A, Freeman J, Salmanzadeh S, Esmaeilian H, Mobarak M, Tabibi R, Jafari Kashi AH, Lotfi Z, Talebzadeh SM, Wickramatillake A, Momtazan M, Hajizadeh Farsani M, Marjani S, Mobarak S. The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19. J Antimicrob Chemother. 2020;75:3366-3372. [PMID: 32812051 DOI: 10.1093/jac/dkaa331] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 17.5] [Reference Citation Analysis]
Number Citing Articles
1 Sokhela S, Bosch B, Hill A, Simmons B, Woods J, Johnstone H, Akpomiemie G, Ellis L, Owen A, Casas CP, Venter WDF. Randomized clinical trial of nitazoxanide or sofosbuvir/daclatasvir for the prevention of SARS-CoV-2 infection. J Antimicrob Chemother 2022:dkac266. [PMID: 35953881 DOI: 10.1093/jac/dkac266] [Reference Citation Analysis]
2 Chen C, Weng T, Chen Y, Kao JH, Chao C. Clinical efficacy of sofosbuvir/daclatasvir in patients with COVID-19: a systematic review and meta-analysis of randomized trials. Expert Review of Clinical Pharmacology. [DOI: 10.1080/17512433.2022.2103539] [Reference Citation Analysis]
3 Al-Kuraishy HM, Al-Gareeb AI, Kaushik A, Kujawska M, Batiha GE. Hemolytic anemia in COVID-19. Ann Hematol 2022. [PMID: 35802164 DOI: 10.1007/s00277-022-04907-7] [Reference Citation Analysis]
4 Sezer A, Halilović-Alihodžić M, Vanwieren AR, Smajkan A, Karić A, Djedović H, Šutković J. A review on drug repurposing in COVID-19: from antiviral drugs to herbal alternatives. J Genet Eng Biotechnol 2022;20:78. [PMID: 35608704 DOI: 10.1186/s43141-022-00353-0] [Reference Citation Analysis]
5 Medhat MA, El-kassas M, Karam-allah H, Al Shafie A, Abd-elsalam S, Moustafa E, Hassany SM, Salama M, Abd Elghafar MS, Sayed H, Badr M, Kamal DT, Shamseldeen A, Ossimi A, Moaz I, El-deen Esmael H, Ezz Eldin AM, Ezzat S, Abdelghaffar H, Abdelghaffar K. Sofosbuvir/Ledipasvir in Combination or Nitazoxanide Alone are Safe and Efficient Treatments for COVID-19 Infection: A Randomized Controlled Trial for Repurposing antivirals. Arab Journal of Gastroenterology 2022. [DOI: 10.1016/j.ajg.2022.04.005] [Reference Citation Analysis]
6 Ahmed YM, Badawy SS, Abdel-Haleem FM. Dibenzo-18-Crown-6-based Carbon Paste Sensors for the Nanomolar Potentiometric Determination of Daclatasvir Dihydrochloride: An Anti-HCV Drug and a Potential Candidate for Treatment of SARS-CoV-2. Microchem J 2022;:107276. [PMID: 35169329 DOI: 10.1016/j.microc.2022.107276] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
7 Charelli LE, de Mattos GC, de Jesus Sousa-Batista A, Pinto JC, Balbino TA. Polymeric nanoparticles as therapeutic agents against coronavirus disease. J Nanopart Res 2022;24:12. [PMID: 35035277 DOI: 10.1007/s11051-022-05396-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Mobarak S, Salasi M, Hormati A, Khodadadi J, Ziaee M, Abedi F, Ebrahimzadeh A, Azarkar Z, Mansour-Ghanaei F, Joukar F, Yeganeh S, Yaghubi Kalurazi T, Naghipour M, Mehrabi Z, Bahadori AR, Yaghoubi S, Moslemi R, Abbaspour Kasgari H, Fakheri H, Moghimi M, Shabani AM, Nekoukar Z, Babamahmoodi F, Davoudi Badabi AR, Davoodi L, Hassaniazad M, Barahimi E, Tousi A, Sadeghi A, Hosamirudsari H, Ali Asgari A, Abdollahi M, Anushiravani A, Shabani M, Shokouhi S, Khajavirad N, Salehi M, Dehghan Manshadi SA, Mousavi H, Zolfaghari F, Azimi E, Zeinali A, Akbarpour E, Merat D, Eslami G, Mousaviasl S, Sayar S, Radmanesh E, Ebrahimzadeh M, Arizavi Z, Jelvay S, Salmanzadeh S, Esmaeilian H, Mobarak M, Karimi J, Poormontaseri Z, Hasooni Bahrini N, Bonyadi A, Dehghani F, Mirzaei H, Noori Jangi M, Pourmasoomi H, Rezaie Keikhaie L, Afshari M, Nateghi Baygi A, Nateghi Baygi H, Levi J, McCann K, Wentzel H, Simmons B, Hill A, Merat S. Evaluation of the effect of sofosbuvir and daclatasvir in hospitalized COVID-19 patients: a randomized double-blind clinical trial (DISCOVER). J Antimicrob Chemother 2021:dkab433. [PMID: 34849957 DOI: 10.1093/jac/dkab433] [Reference Citation Analysis]
9 Kishk A, Pacheco MP, Sauter T. DCcov: Repositioning of drugs and drug combinations for SARS-CoV-2 infected lung through constraint-based modeling. iScience 2021;24:103331. [PMID: 34723158 DOI: 10.1016/j.isci.2021.103331] [Reference Citation Analysis]
10 Hatami B, Rabbani A, Ketabi Moghadam P, Rajabnia M, Borhany H. A Case Series of Variable Manifestations of COVID-19 in Liver Transplant Recipients. Middle East J Dig Dis 2021;13:363-9. [DOI: 10.34172/mejdd.2021.248] [Reference Citation Analysis]
11 Kim SB, Ryoo S, Huh K, Joo EJ, Kim YJ, Choi WS, Kim YJ, Yoon YK, Heo JY, Seo YB, Jeong SJ, Park DA, Yu SY, Lee HJ, Kim J, Jin Y, Park J, Peck KR, Choi M, Yeom JS; Korean Society of Infectious Diseases (KSID). Revised Korean Society of Infectious Diseases/National Evidence-based Healthcarea Collaborating Agency Guidelines on the Treatment of Patients with COVID-19. Infect Chemother 2021;53:166-219. [PMID: 34409790 DOI: 10.3947/ic.2021.0303] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
12 Abbass S, Kamal E, Salama M, Salman T, Sabry A, Abdel-Razek W, Helmy S, Abdelgwad A, Sakr N, Elgazzar M, Einar M, Farouk M, Saif M, Shehab I, El-Hosieny E, Mansour M, Mahdi D, Tharwa ES, Salah M, Elrouby O, Waked I. Efficacy and safety of sofosbuvir plus daclatasvir or ravidasvir in patients with COVID-19: A randomized controlled trial. J Med Virol 2021. [PMID: 34379337 DOI: 10.1002/jmv.27264] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Gil Martínez V, Avedillo Salas A, Santander Ballestín S. Antiviral Therapeutic Approaches for SARS-CoV-2 Infection: A Systematic Review. Pharmaceuticals (Basel) 2021;14:736. [PMID: 34451833 DOI: 10.3390/ph14080736] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
14 M Mansour S, N Shamma R, A Ahmed K, A Sabry N, Esmat G, A Mahmoud A, Maged A. Safety of inhaled ivermectin as a repurposed direct drug for treatment of COVID-19: A preclinical tolerance study. Int Immunopharmacol 2021;99:108004. [PMID: 34333358 DOI: 10.1016/j.intimp.2021.108004] [Reference Citation Analysis]
15 Sayad B, Khodarahmi R, Najafi F, Miladi R, Mohseni Afshar Z, Mansouri F, Rahimi Z, Shirvani M, Salimi M, Vaziri S, Janbakhsh A, Khosravi Shadmani F, Bozorgomid A, Zamanian MH, Afsharian M. Efficacy and safety of sofosbuvir/velpatasvir versus the standard of care in adults hospitalized with COVID-19: a single-centre, randomized controlled trial. J Antimicrob Chemother 2021;76:2158-67. [PMID: 34037760 DOI: 10.1093/jac/dkab152] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 El-Bendary M, Abd-Elsalam S, Elbaz T, El-Akel W, Cordie A, Elhadidy T, Elalfy H, Farid K, Elegezy M, El-Badrawy A, Neamatallah M, Abd Elghafar M, Salama M, AbdAllah M, Essam M, El-Shazly M, Esmat G. Efficacy of combined Sofosbuvir and Daclatasvir in the treatment of COVID-19 patients with pneumonia: a multicenter Egyptian study. Expert Rev Anti Infect Ther 2021;:1-5. [PMID: 34225541 DOI: 10.1080/14787210.2021.1950532] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Liatsos GD. Controversies’ clarification regarding ribavirin efficacy in measles and coronaviruses: Comprehensive therapeutic approach strictly tailored to COVID-19 disease stages. World J Clin Cases 2021; 9(19): 5135-5178 [PMID: 34307564 DOI: 10.12998/wjcc.v9.i19.5135] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Lai CC, Chao CM, Hsueh PR. Clinical efficacy of antiviral agents against coronavirus disease 2019: A systematic review of randomized controlled trials. J Microbiol Immunol Infect 2021:S1684-1182(21)00135-3. [PMID: 34253490 DOI: 10.1016/j.jmii.2021.05.011] [Reference Citation Analysis]
19 Ng YL, Salim CK, Chu JJH. Drug repurposing for COVID-19: Approaches, challenges and promising candidates. Pharmacol Ther 2021;228:107930. [PMID: 34174275 DOI: 10.1016/j.pharmthera.2021.107930] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Zein AFMZ, Sulistiyana CS, Raffaello WM, Wibowo A, Pranata R. Sofosbuvir with daclatasvir and the outcomes of patients with COVID-19: a systematic review and meta-analysis with GRADE assessment. Postgrad Med J 2021:postgradmedj-2021-140287. [PMID: 34103373 DOI: 10.1136/postgradmedj-2021-140287] [Reference Citation Analysis]
21 Mei M, Tan X. Current Strategies of Antiviral Drug Discovery for COVID-19. Front Mol Biosci 2021;8:671263. [PMID: 34055887 DOI: 10.3389/fmolb.2021.671263] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
22 Raj K, Kaur K, Gupta GD, Singh S. Current understanding on molecular drug targets and emerging treatment strategy for novel coronavirus-19. Naunyn Schmiedebergs Arch Pharmacol 2021;394:1383-402. [PMID: 33961065 DOI: 10.1007/s00210-021-02091-5] [Reference Citation Analysis]
23 Scavone C, Mascolo A, Rafaniello C, Sportiello L, Trama U, Zoccoli A, Bernardi FF, Racagni G, Berrino L, Castaldo G, Coscioni E, Rossi F, Capuano A. Therapeutic strategies to fight COVID-19: Which is the status artis? Br J Pharmacol 2021. [PMID: 33960398 DOI: 10.1111/bph.15452] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
24 Mongia A, Saha SK, Chouzenoux E, Majumdar A. A computational approach to aid clinicians in selecting anti-viral drugs for COVID-19 trials. Sci Rep 2021;11:9047. [PMID: 33907209 DOI: 10.1038/s41598-021-88153-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
25 Jirjees F, Saad AK, Al Hano Z, Hatahet T, Al Obaidi H, Dallal Bashi YH. COVID-19 Treatment Guidelines: Do They Really Reflect Best Medical Practices to Manage the Pandemic? Infect Dis Rep 2021;13:259-84. [PMID: 33915690 DOI: 10.3390/idr13020029] [Reference Citation Analysis]
26 Lisco G, De Tullio A, Jirillo E, Giagulli VA, De Pergola G, Guastamacchia E, Triggiani V. Thyroid and COVID-19: a review on pathophysiological, clinical and organizational aspects. J Endocrinol Invest 2021;44:1801-14. [PMID: 33765288 DOI: 10.1007/s40618-021-01554-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 19.0] [Reference Citation Analysis]
27 Spera AM. Are nucleotide inhibitors, already used for treating hepatitis C virus infection, a potential option for the treatment of COVID-19 compared with standard of care? A literature review. World J Virol 2021; 10(2): 53-61 [PMID: 33816150 DOI: 10.5501/wjv.v10.i2.53] [Reference Citation Analysis]
28 Khan S, Attar F, Bloukh SH, Sharifi M, Nabi F, Bai Q, Khan RH, Falahati M. A review on the interaction of nucleoside analogues with SARS-CoV-2 RNA dependent RNA polymerase. Int J Biol Macromol 2021;181:605-11. [PMID: 33766591 DOI: 10.1016/j.ijbiomac.2021.03.112] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
29 Yang Y, Cui X, Wei H, Guo C, Zhang Y. Potential Anti-Coronavirus Agents and the Pharmacologic Mechanisms. Drug Des Devel Ther 2021;15:1213-23. [PMID: 33762818 DOI: 10.2147/DDDT.S293216] [Reference Citation Analysis]
30 Gomez Marti JL, Brufsky AM. Considerations of the effects of commonly investigated drugs for COVID-19 in the cholesterol synthesis pathway. Expert Opin Pharmacother 2021;22:947-52. [PMID: 33703986 DOI: 10.1080/14656566.2021.1897104] [Reference Citation Analysis]
31 Indari O, Jakhmola S, Manivannan E, Jha HC. An Update on Antiviral Therapy Against SARS-CoV-2: How Far Have We Come? Front Pharmacol 2021;12:632677. [PMID: 33762954 DOI: 10.3389/fphar.2021.632677] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 13.0] [Reference Citation Analysis]
32 Khani E, Khiali S, Entezari-Maleki T. Potential COVID-19 Therapeutic Agents and Vaccines: An Evidence-Based Review. J Clin Pharmacol 2021;61:429-60. [PMID: 33511638 DOI: 10.1002/jcph.1822] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
33 Shoaib MH, Ahmed FR, Sikandar M, Yousuf RI, Saleem MT. A Journey From SARS-CoV-2 to COVID-19 and Beyond: A Comprehensive Insight of Epidemiology, Diagnosis, Pathogenesis, and Overview of the Progress into Its Therapeutic Management. Front Pharmacol 2021;12:576448. [PMID: 33732150 DOI: 10.3389/fphar.2021.576448] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Gong WJ, Zhou T, Wu SL, Ye JL, Xu JQ, Zeng F, Su YY, Han Y, Lv YN, Zhang Y, Cai XF. A retrospective analysis of clinical efficacy of ribavirin in adults hospitalized with severe COVID-19. J Infect Chemother 2021;27:876-81. [PMID: 33676844 DOI: 10.1016/j.jiac.2021.02.018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
35 Españo E, Kim D, Kim J, Park SK, Kim JK. COVID-19 Antiviral and Treatment Candidates: Current Status. Immune Netw 2021;21:e7. [PMID: 33728100 DOI: 10.4110/in.2021.21.e7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Roozbeh F, Saeedi M, Alizadeh-Navaei R, Hedayatizadeh-Omran A, Merat S, Wentzel H, Levi J, Hill A, Shamshirian A. Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: a double-blind, randomized controlled trial. J Antimicrob Chemother 2021;76:753-7. [PMID: 33338232 DOI: 10.1093/jac/dkaa501] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 26.0] [Reference Citation Analysis]
37 Simmons B, Wentzel H, Mobarak S, Eslami G, Sadeghi A, Ali Asgari A, Abbaspour Kasgari H, Tirgar Fakheri H, Merat S, Hill A. Sofosbuvir/daclatasvir regimens for the treatment of COVID-19: an individual patient data meta-analysis. J Antimicrob Chemother. 2021;76:286-291. [PMID: 33063117 DOI: 10.1093/jac/dkaa418] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
38 Rebold N, Holger D, Alosaimy S, Morrisette T, Rybak M. COVID-19: Before the Fall, An Evidence-Based Narrative Review of Treatment Options. Infect Dis Ther 2021;10:93-113. [PMID: 33495967 DOI: 10.1007/s40121-021-00399-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
39 Pagliano P, Scarpati G, Sellitto C, Conti V, Spera AM, Ascione T, Piazza O, Filippelli A. Experimental Pharmacotherapy for COVID-19: The Latest Advances. J Exp Pharmacol 2021;13:1-13. [PMID: 33442304 DOI: 10.2147/JEP.S255209] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
40 Tam NM, Pham MQ, Ha NX, Nam PC, Phung HTT. Computational estimation of potential inhibitors from known drugs against the main protease of SARS-CoV-2. RSC Adv 2021;11:17478-86. [DOI: 10.1039/d1ra02529e] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
41 Chan HT, Chao CM, Lai CC. Sofosbuvir/daclatasvir in the treatment of COVID-19 infection: A meta-analysis. J Infect 2021;82:e34-5. [PMID: 33373651 DOI: 10.1016/j.jinf.2020.12.021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
42 Hanafy AS, Abd-Elsalam S. Challenges in COVID-19 drug treatment in patients with advanced liver diseases: A hepatology perspective. World J Gastroenterol 2020; 26(46): 7272-7286 [PMID: 33362383 DOI: 10.3748/wjg.v26.i46.7272] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
43 Khalili H, Nourian A, Ahmadinejad Z, Emadi Kouchak H, Jafari S, Dehghan Manshadi SA, Rasolinejad M, Kebriaeezadeh A. Efficacy and safety of sofosbuvir/ ledipasvir in treatment of patients with COVID-19; A randomized clinical trial. Acta Biomed 2020;91:e2020102. [PMID: 33525212 DOI: 10.23750/abm.v91i4.10877] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
44 Ju J, Li X, Kumar S, Jockusch S, Chien M, Tao C, Morozova I, Kalachikov S, Kirchdoerfer RN, Russo JJ. Nucleotide analogues as inhibitors of SARS-CoV Polymerase. Pharmacol Res Perspect 2020;8:e00674. [PMID: 33124786 DOI: 10.1002/prp2.674] [Cited by in Crossref: 10] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
45 Kumar P, Kulkarni A, Sharma M, Rao PN. Repurposing Hepatitis C Direct-Acting Antivirals Against COVID-19. J Clin Exp Hepatol 2021;11:273-5. [PMID: 33071519 DOI: 10.1016/j.jceh.2020.10.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]